Lin Quek
Associate Director, Gene Therapy Research Fractyl Health
Seminars
Wednesday 15th April 2026
Achieving Better Potency & Tolerability Through Pancreas-focused GLP- 1R Agonism with Rejuva Pancreatic Gene Therapy
1:00 pm
- Expression of GLP-1 locally within the pancreas, with low circulating GLP-1 levels, overcomes dose-limiting tolerability of pharmacologic therapy
- Local delivery of Rejuva pancreatic gene therapy avoids safety concerns of high dose systemic gene therapy
- Preclinical results support FIH study initiation in 2026
